Bone Biologics Prices 50 Million Underwritten Public Offering

BURLINGTON, Mass.–(BUSINESS WIRE)– Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the pricing of an underwritten public offering of common stock. Bone Biologics is selling 2,538,071 shares of its common stock in the offering. The shares of…Read More